These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21937505)

  • 1. Fatty liver index in polycystic ovary syndrome.
    Lerchbaum E; Gruber HJ; Schwetz V; Giuliani A; Möller R; Pieber TR; Obermayer-Pietsch B
    Eur J Endocrinol; 2011 Dec; 165(6):935-43. PubMed ID: 21937505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
    Polyzos SA; Goulis DG; Kountouras J; Mintziori G; Chatzis P; Papadakis E; Katsikis I; Panidis D
    Hormones (Athens); 2014; 13(4):519-31. PubMed ID: 25402369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fatty liver index is associated with increased mortality in subjects referred to coronary angiography.
    Lerchbaum E; Pilz S; Grammer TB; Boehm BO; Stojakovic T; Obermayer-Pietsch B; März W
    Nutr Metab Cardiovasc Dis; 2013 Dec; 23(12):1231-8. PubMed ID: 23557879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lipid accumulation product is associated with impaired glucose tolerance in PCOS women.
    Wehr E; Gruber HJ; Giuliani A; Möller R; Pieber TR; Obermayer-Pietsch B
    J Clin Endocrinol Metab; 2011 Jun; 96(6):E986-90. PubMed ID: 21470992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome.
    Wehr E; Pilz S; Schweighofer N; Giuliani A; Kopera D; Pieber TR; Obermayer-Pietsch B
    Eur J Endocrinol; 2009 Oct; 161(4):575-82. PubMed ID: 19628650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS).
    Hossain N; Stepanova M; Afendy A; Nader F; Younossi Y; Rafiq N; Goodman Z; Younossi ZM
    Scand J Gastroenterol; 2011 Apr; 46(4):479-84. PubMed ID: 21114431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
    Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
    Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic syndrome in Mediterranean women with polycystic ovary syndrome: when and how to predict its onset.
    Espinós-Gómez JJ; Rodriguez-Espinosa J; Ordóñez-Llanos J; Calaf-Alsina J
    Gynecol Endocrinol; 2012 Apr; 28(4):264-8. PubMed ID: 21962027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease.
    Motamed N; Sohrabi M; Ajdarkosh H; Hemmasi G; Maadi M; Sayeedian FS; Pirzad R; Abedi K; Aghapour S; Fallahnezhad M; Zamani F
    World J Gastroenterol; 2016 Mar; 22(10):3023-30. PubMed ID: 26973398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome.
    Vassilatou E; Lafoyianni S; Vassiliadi DA; Ioannidis D; Paschou SA; Mizamtsidi M; Panagou M; Vryonidou A
    Maturitas; 2018 Oct; 116():1-7. PubMed ID: 30244768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome.
    Vassilatou E; Lafoyianni S; Vryonidou A; Ioannidis D; Kosma L; Katsoulis K; Papavassiliou E; Tzavara I
    Hum Reprod; 2010 Jan; 25(1):212-20. PubMed ID: 19887498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.
    Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M
    Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: associated factors and noninvasive fibrosis staging in a single Brazilian center.
    Taranto DOL; Guimarães TCM; Couto CA; Cândido AL; Azevedo RCS; Mattos FS; Elias MLC; Reis FM; Rocha ALL; Faria LC
    Arch Endocrinol Metab; 2020; 64(3):235-242. PubMed ID: 32555989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Markers of visceral obesity and cardiovascular risk in patients with polycystic ovarian syndrome.
    Gateva AT; Kamenov ZA
    Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):161-6. PubMed ID: 22727921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes.
    Graff SK; Mário FM; Alves BC; Spritzer PM
    Fertil Steril; 2013 Oct; 100(4):1081-8. PubMed ID: 23830153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinol-binding protein 4 levels are elevated in polycystic ovary syndrome women with obesity and impaired glucose metabolism.
    Hahn S; Backhaus M; Broecker-Preuss M; Tan S; Dietz T; Kimmig R; Schmidt M; Mann K; Janssen OE
    Eur J Endocrinol; 2007 Aug; 157(2):201-7. PubMed ID: 17656599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sonographic measurement of mesenteric fat predicts presence of fatty liver among subjects with polycystic ovary syndrome.
    Ma RC; Liu KH; Lam PM; Cheung LP; Tam WH; Ko GT; Chan MH; Ho CS; Lam CW; Chu WC; Tong PC; So WY; Chan JC; Chow CC
    J Clin Endocrinol Metab; 2011 Mar; 96(3):799-807. PubMed ID: 21190980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptom patterns and phenotypic subgrouping of women with polycystic ovary syndrome: association between endocrine characteristics and metabolic aberrations.
    Huang CC; Tien YJ; Chen MJ; Chen CH; Ho HN; Yang YS
    Hum Reprod; 2015 Apr; 30(4):937-46. PubMed ID: 25662806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vigorous exercise is associated with superior metabolic profiles in polycystic ovary syndrome independent of total exercise expenditure.
    Greenwood EA; Noel MW; Kao CN; Shinkai K; Pasch LA; Cedars MI; Huddleston HG
    Fertil Steril; 2016 Feb; 105(2):486-93. PubMed ID: 26551442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation between C-reactive protein and body mass index in patients with polycystic ovarian syndrome.
    Moradi S; Mollabashi M; Kerman SR
    Gynecol Endocrinol; 2011 Jul; 27(7):480-5. PubMed ID: 20836727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.